Announcements
- Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
- Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
- Rhythm Pharmaceuticals Announces New Employment Inducement Grants
- Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
- Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
- Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
- Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
- Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
- Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
- Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
More ▼
Key statistics
On Tuesday, Rhythm Pharmaceuticals Inc (1RV:DUS) closed at 38.18, -20.46% below its 52-week high of 48.00, set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 35.73 |
---|---|
High | 38.18 |
Low | 35.53 |
Bid | 36.69 |
Offer | 37.90 |
Previous close | 35.98 |
Average volume | 5.00 |
---|---|
Shares outstanding | 60.96m |
Free float | 57.37m |
P/E (TTM) | -- |
Market cap | 2.42bn USD |
EPS (TTM) | -3.19 USD |
Data delayed at least 15 minutes, as of Apr 30 2024 18:30 BST.
More ▼